Pharmaco-genomic mutation labeling

• US 9,384,323 B1
• Filed: 01/09/2009
• Issued: 07/05/2016
• Est. Priority Date: 10/18/2002
• Status: Expired due to Fees

• Current Assignee: Antonia Teresita Ancheta Maninang, Dennis Fernandez
• Original Assignee: Antonia Teresita Ancheta Maninang, Dennis Fernandez
• Inventors: Fernandez, Dennis S., Maninang, Antonia Teresita Ancheta
• Primary Examiner(s): Lin, Jerry
• Application Number:
  US12/351,552
• Time in Patent Office: 2,734 Days
• Field of Search: 702/19
• US Class Current: 1/1
• CPC Class Codes: G16B 20/00 ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• CPC Class Codes: G16B 20/20 Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• CPC Class Codes: G16B 30/00 ICT specially adapted for sequence analysis involving nucleotides or amino acids
• CPC Class Codes: G16B 5/00 ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• CPC Class Codes: G16B 5/20 Probabilistic models
• CPC Class Codes: G16B 99/00 Subject matter not provided for in other groups of this subclass
• CPC Class Codes: G16H 10/20 for electronic clinical trials or questionnaires
• CPC Class Codes: G16H 70/20 relating to practices or guidelines
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Electronic label processor compares bioinformatic values to determine pharmaco-genomic mutation associated with host. Label display indicates pharmaco-genomic mutation, which is network-accessible for modified medical message. Bioinformatic values are determined preferably at different times.

Claims

1. A mobile hand-held wireless sensor-based electronic system for displaying a comparison of a first bioinformatic value and a second bioinformatic value to detect GPCR pharmaco-genomic mutation, the system comprising:

a processor,

a display,

and a storage;

wherein said processor is coupled to the display and displays said comparison,

wherein said comparison uses said processor to determine a pharmaco-genomic mutation associated with a host, said comparison and associated pharmaco-genomic mutation being stored in the storage, and wherein said processor is effective to access said comparison and associated pharmaco-genomic mutation from storage and indicate said pharmaco-genomic mutation on said display,

wherein said pharmaco-genomic mutation is determined electronically by the processor automatically analyzing said compared bioinformatic values to detect G protein-coupled receptors (GPCR) molecular target and variant alleles,

wherein the processor, display and storage functionally embody an electronic medical label using a rule-based advisor expert system that electronically generates an audio-visual alert comprising a genetic mutation and pharmaco-kinetic clinical indication to one or more time-critical or urgent-care medical professional, said rule-based advisor expert system determining one or more patient pharmaco-genomic profile according to the compared bioinformatic values associated with the host to generate further via the audio-visual alert including one or more monitored risk and appropriate medication associated with the detected GPCR molecular target and variant alleles, thereby optimally expediting GPCR-related medication using the electronic medical label according to the rule-based advisor expert system automated analysis of one or more host susceptibility or predisposition to pharmaco-genomic or pharmaco-kinetic toxicity or other adverse host reaction or side effects to one or more food, drug or treatment;

wherein the processor, display and storage are embodied functionally in a mobile hand-held system further comprising a sensor integrated therewith that is wirelessly accessible via a wireless communication network, such sensor sensing GPCR molecular target and variant alleles using integrated chip refractive-index micro-interferometry detection using coherent VCSEL, laser diode, or He—

Ne laser source, etched substrate capillary channel for sample reception and analysis, and reflected laser-light reflection photodetector, and the sensor further senses GPCR molecular target and variant alleles using an affinity-based biosensor based on optical evanescent wave detector using flow-based surface plasmon resonance in micro-fabricated integrated fluidic cartridge to capture tagged proteins, thiol coupling, or coil-coil interaction, wherein resonance angle is continuously monitored to detect changes in refractive resonance angle and refractive index corresponding to changes in mass when certain ligand binds to, or dissociates from, immobilized binding partner;

wherein said processor that determines the pharmaco-genomic mutation and rule-based advisor expert system comprises one or more systolic array-based fuzzy logic and Bayesian or neural network-implemented virtual cell systems biology software that models and simulates perturbation and mutagenesis stimulation to predict GPCR pharmaco-genomic mutation behavior according to host drug metabolism, transport, distribution and excretion automatically using sensed GPCR molecular target and variant alleles using the affinity-based biosensor having the optical evanescent wave detector and integrated chip refractive-index micro-interferometry detection based on pair-wise labeled relationships between proteins, genes and RNA transcripts further detected by said processor that determines the pharmaco-genomic mutation and rule-based advisor expert system using semiconductor nanocrystal or quantum-dot device that links or bonds to one or more affinity molecules of an analyte comprising sensed GPCR molecular target and variant alleles, whereupon such nanocrystal probe in response to a first energy associated with a presence of sensed GPCR molecular target and variant alleles excites the nanocrystal or quantum-dot device causing such probe to provide a second energy or generate or fluoresce a distinct wavelength signal indicating GPCR pharmaco-genomic mutation to alert potential or actual medical associated risk with organ transplant, paternity identification, genetically-modified agricultural crops, antisense and gene vaccine or therapy;

wherein said processor comprises the one or more systolic array that models and simulates perturbation and mutagenesis stimulation to predict GPCR pharmaco-genomic mutation behavior according to host drug metabolism, transport, distribution and excretion using sensed GPCR molecular target and variant alleles predictably to alert potential or actual medical associated risk with organ transplant, paternity identification, genetically-modified agricultural crops, antisense, and gene vaccine or therapy based on pair-wise labeled relationships between proteins, genes and RNA transcripts further detected by said processor when determining the pharmaco-genomic mutation using the semiconductor nanocrystal or quantum-dot device that links or bonds to one or more affinity molecules of an analyte comprising sensed GPCR molecular target and variant alleles, whereupon such nanocrystal probe in response to first energy associated with a presence of sensed GPCR molecular target and variant alleles excites the nanocrystal or quantum-dot device causing such probe to provide second energy or generate or fluoresce a distinct wavelength signal indicating GPCR pharmaco-genomic mutation, thereby automatically enabling the one or more systolic array to alert potential or actual medical associated risk with organ transplant, paternity identification, genetically-modified agricultural crops, antisense, and gene vaccine or therapy based on pair-wise labeled relationships between proteins, genes and RNA transcripts to predict GPCR pharmaco-genomic mutation behavior according to host drug metabolism, transport, distribution and excretion using sensed GPCR molecular target and variant alleles.

2. The system of claim 1 wherein:

said processor communicates with the system through a network interface, the system being configured to access the storage through the interface.

3. The system of claim 1 wherein:

said pharmaco-genomic mutation is effective to indicate a medical message and said processor displays a modified medical message.

4. The system of claim 1:

further comprising a means for storing and comparing a third bioinformatic value and a fourth bioinformatic value to determine an additional pharmaco-genomic mutation associated with a different host, said processor being coupled to another system,

wherein the other system comprises a means for indicating the pharmaco-genomic mutation associated with said different host, the processor accesses the comparison and associated additional pharmaco-genomic mutation from the storage.

5. The system of claim 1 wherein:

said processor determines the first and second bioinformatic values at different times.

6. A mobile hand-held wireless sensor-based electronic method for displaying a pharmaco-genomic mutation associated with GPCR, the method comprising steps:

comparing by a processor a first bioinformatic value and a second bioinformatic value to determine a pharmaco-genomic mutation; and

displaying by the processor a determination of the pharmaco-genomic mutation,

wherein the processor automatically analyzes said compared bioinformatic values to detect G protein-coupled receptors (GPCR) molecular target and variant alleles,

wherein the processor functionally embodies an electronic medical label using a rule-based advisor expert system that electronically generates an audio-visual alert comprising a genetic mutation and pharmaco-kinetic clinical indication to one or more time-critical or urgent-care medical professional, said rule-based advisor expert system determining one or more patient pharmaco-genomic profile according to the compared bioinformatic values associated with the host to generate further via the audio-visual alert including one or more monitored risk and appropriate medication associated with the detected GPCR molecular target and variant alleles, thereby optimally expediting GPCR-related medication using the electronic medical label according to the rule-based advisor expert system automated analysis of one or more host susceptibility or predisposition to pharmaco-genomic or pharmaco-kinetic toxicity or other adverse host reaction or side effects to one or more food, drug or treatment;

wherein the processor, display and storage are embodied functionally in a mobile hand-held system further comprising a sensor integrated therewith that is wirelessly accessible via a wireless communication network, such sensor sensing GPCR molecular target and variant alleles using integrated chip refractive-index micro-interferometry detection using coherent VCSEL, laser diode, or He—

Ne laser source, etched substrate capillary channel for sample reception and analysis, and reflected laser-light reflection photodetector, and the sensor further senses GPCR molecular target and variant alleles using an affinity-based biosensor based on optical evanescent wave detector using flow-based surface plasmon resonance in micro-fabricated integrated fluidic cartridge to capture tagged proteins, thiol coupling, or coil-coil interaction, wherein resonance angle is continuously monitored to detect changes in refractive resonance angle and refractive index corresponding to changes in mass when certain ligand binds to, or dissociates from, immobilized binding partner;

wherein said processor that determines the pharmaco-genomic mutation and rule-based advisor expert system comprises one or more systolic array-based fuzzy logic and Bayesian or neural network-implemented virtual cell systems biology software that models and simulates perturbation and mutagenesis stimulation to predict GPCR pharmaco-genomic mutation behavior according to host drug metabolism, transport, distribution and excretion automatically using sensed GPCR molecular target and variant alleles using the affinity-based biosensor having the optical evanescent wave detector and integrated chip refractive-index micro-interferometry detection based on pair-wise labeled relationships between proteins, genes and RNA transcripts further detected by said processor that determines the pharmaco-genomic mutation and rule-based advisor expert system using semiconductor nanocrystal or quantum-dot device that links or bonds to one or more affinity molecules of an analyte comprising sensed GPCR molecular target and variant alleles, whereupon such nanocrystal probe in response to a first energy associated with a presence of sensed GPCR molecular target and variant alleles excites the nanocrystal or quantum-dot device causing such probe to provide a second energy or generate or fluoresce a distinct wavelength signal indicating GPCR pharmaco-genomic mutation to alert potential or actual medical associated risk with organ transplant, paternity identification, genetically-modified agricultural crops, antisense and gene vaccine or therapy;

wherein said processor comprises the one or more systolic array that models and simulates perturbation and mutagenesis stimulation to predict GPCR pharmaco-genomic mutation behavior according to host drug metabolism, transport, distribution and excretion using sensed GPCR molecular target and variant alleles predictably to alert potential or actual medical associated risk with organ transplant, paternity identification, genetically-modified agricultural crops, antisense, and gene vaccine or therapy based on pair-wise labeled relationships between proteins, genes and RNA transcripts further detected by said processor when determining the pharmaco-genomic mutation using the semiconductor nanocrystal or quantum-dot device that links or bonds to one or more affinity molecules of an analyte comprising sensed GPCR molecular target and variant alleles, whereupon such nanocrystal probe in response to first energy associated with a presence of sensed GPCR molecular target and variant alleles excites the nanocrystal or quantum-dot device causing such probe to provide second energy or generate or fluoresce a distinct wavelength signal indicating GPCR pharmaco-genomic mutation, thereby automatically enabling the one or more systolic array to alert potential or actual medical associated risk with organ transplant, paternity identification, genetically-modified agricultural crops, antisense, and gene vaccine or therapy based on pair-wise labeled relationships between proteins, genes and RNA transcripts to predict GPCR pharmaco-genomic mutation behavior according to host drug metabolism, transport, distribution and excretion using sensed GPCR molecular target and variant alleles.

7. The method of claim 6 wherein:

said processor communicates with the system through a network interface, the system being configured to access the storage through the interface.

8. The method of claim 6 wherein:

said pharmaco-genomic mutation is effective to indicate a medical message and said processor displays a modified medical message.

9. The method of claim 6:

further comprising storing and comparing a third bioinformatic value and a fourth bioinformatic value to determine an additional pharmaco-genomic mutation associated with a different host, said processor being coupled to another system,

wherein the other indicates the pharmaco-genomic mutation associated with said different host, the processor accesses the comparison and associated additional pharmaco-genomic mutation from the storage.

10. The method of claim 6 wherein:

said processor determines the first and second bioinformatic values at different times.